Eton Pharmaceuticals (ETON) Share-based Compensation (2017 - 2026)

Eton Pharmaceuticals has disclosed Share-based Compensation across 10 years of filings, most recently posting $8.0 million for Q2 2026.

• In Q2 2026, Share-based Compensation fell 6.17% year-over-year to $8.0 million; the TTM figure through Jun 2026 stood at $8.0 million (down 6.17% YoY), while the FY2025 annual figure was $5.9 million, changed 0.12% from the prior year.
• Share-based Compensation came in at $8.0 million for Q2 2026 at Eton Pharmaceuticals, up from $1.1 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $8.5 million in Q2 2025 to a low of $750000.0 in Q4 2023.
• Average Share-based Compensation over 5 years is $4.7 million, with a median of $4.9 million recorded in 2023.
• Year-over-year, Share-based Compensation jumped 67.02% in 2022 and declined 15.35% in 2023.
• Over 5 years, Share-based Compensation stood at $886000.0 in 2022, then slipped by 15.35% to $750000.0 in 2023, then grew by 4.27% to $782000.0 in 2024, then surged by 43.73% to $1.1 million in 2025, then surged by 610.23% to $8.0 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $8.0 million in Q2 2026, $1.1 million in Q4 2025, and $6.0 million in Q3 2025.